Earnshaw SR, Taylor TN, McDade CL. Pharmacoeconomics and the drug development process.. In: Yih Y, editors. Handbook of healthcare delivery systems. Boca Raton: FL. CRC Press; 2010.
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the 9th Canadian Immunization Conference; December 2010. Previously presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Mladsi DM, Redekop K, Goettsch A, Earnshaw SR. Challenges and insights in establishing and communicating the economic value of companion diagnostics. Presented at the 2010 ISPOR 13th Annual European Congress; November 2010. Prague, Czech Republic.
Mladsi D, Earnshaw S, Ronquest NA, Keith M. The threshold pricing model: not just another cost-effectiveness model. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A332.
Mladsi D, Earnshaw S, Akashi-Ronquest N, Keith M. Proposed methods for conducting sensitivity analyses on threshold-derived estimates of value-based price and product profiles of early stage drugs. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A333.
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.
Jackson D, Earnshaw SR, Farkouh R, Schwamm L. Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective. Am J Neuroradiol. 2010 Oct 1;31(9):1669-74.
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2010.
Rinaldi F, Hwang S, Strutton D, Earnshaw S, Farkouh R. Clinical and economic impact of 13-valent pneumococcal conjugate vaccination in Singapore and Hong Kong. Poster presented at the 2010 ISPOR 15th Annual International Meeting; June 2, 2010.
Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.
Earnshaw S, Pignone M, Fendrick AM, Scheiman J, McDade C. Cost-effectiveness of proton pump inhibitors for prevention of gastrointestinal adverse events when using aspirin for primary cardiovascular prevention. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A166.
Jackson D, Earnshaw S, Farkouh RA, Schwamm LH. Cost-effectiveness of perfusion imaging with computed tomography to identify patients for intravenous thrombolysis: a hospital perspective. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A175.
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Earnshaw SR, Graham CN, Amonkar MM, Poston SA, Barr CE. Cost-effectiveness of ibandronate intravenous injection in the treatment of US women with postmenopausal osteoporosis. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Earnshaw SR, Pignone M, Tice J, Pletcher M. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Poster presented at the Annual Meeting of the Institute for Operations Research and the Management Sciences; November 2006.
Cowell W, Amonkar M, Cooper A, Earnshaw SR, Beard SM, Lynch N, Middelhoven H. Ibandronate vs. alendrolate: a cost-effectiveness analysis using persist results. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Shearer A, Gazzard B, Graham CN, Davis EA, Mauskopf J, Kitahata M, Saag MS, Earnshaw SR. Simulation modeling of adherence and resistance on long-term outcomes in HIV. Poster presented at the Infectious Disease Society of America 44th Annual Meeting; October 15, 2006.
Graham CN, Earnshaw SR, Smith DG, Hogue S, Gitchell J, Marsh H, Becker W, Saunders M. Assessing the impact of smoking cessation therapies on a managed care organization's budget. Poster presented at the Academy of Managed Care Pharmacy Educational Conference; October 7, 2006.
Earnshaw SR, Beard SM, Lynch NO, Cooper A, Cowell W, Middelhoven H. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK propsective rct. Poster presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research; September 19, 2006.
Schnitzler MA, Earnshaw SR, Graham CN, Irish WD, Sato R. Lifetime cost-effectiveness of calcineruin inhibitor-free immunosuppressive treatment after de novo renal transplantation. Poster presented at the World Transplant Congress; July 27, 2006.
Earnshaw SR, Beard SM, Lynch NO, Cowell W. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK. Poster presented at the European League Against Rheumatism Annual European Congress of Rheumatology; June 24, 2006.
Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson K. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA.
Earnshaw SR, Moride Y, Moshyk A, Rochon S. Cost-effectiveness of macugen compared to photodynamic therapy (PDT) with verteporfin and standard care in the treatment of subfoveal wet age-related macular degeneration (AMD) in the elderly in Canada. Poster presented at the Third Annual Canadian Joint Therapeutics Congress, Canadian Association for Population Therapeutics; May 13, 2006. Toronto, Canada.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.
Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.
Earnshaw SR, Gricar J. Good practices for high quality decision analytic models. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 6, 2006.
Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.
Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 Mar 7;144(5):326-36.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2006 World Ophthalmology Congress; February 2006. Previously presented at the ISPOR 8th Annual European Congress.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.